Podbit · The Peter Attia Drive
PCR was conceptually brilliant but practically useless until scientists needed a polymerase that could survive being heated to 95°C cycle after cycle. That enzyme had been sitting in public culture collections since 1969, isolated from a Yellowstone hot spring by a microbiologist who just wanted to know if life could exist at near-boiling temperatures.
Where this was said
At 27:40 · chapter starts 21:00
The story begins in Brazil in the 1940s, where pharmacologist Maurício Rocha e Silva was testing the hypothesis that pit viper venom caused circulatory shock by releasing histamine from blood plasma. The hypothesis was wrong. The venom released something else entirely: a potent vasodilating peptide he named bradykinin. A decade and a half later, Rocha e Silva's graduate student Sérgio Ferreira noticed that bradykinin in plasma was more active than synthetic bradykinin, and traced the discrepancy to a second family of venom peptides — Bradykinin Potentiating Factors (BPFs) — that protected bradykinin from degradation. [1] — Peter Attia "ACE inhibitor chain: 70 years of fieldwork: The entire ACE inhibitor drug class, from bradykinin's discovery in the 1940s to captopril's FD…" 26:30 Ferreira carried powdered BPF to London, to a lab studying pulmonary circulation, where postdoc Kevin Ng had discovered that angiotensin I converts to angiotensin II in the lungs. A key convergence: the same enzyme that destroyed bradykinin was also making angiotensin II — a dual-function regulator sitting at the center of the blood pressure system. Squibb's chemists used the smallest active BPF peptide as a structural lead and designed captopril, the first oral ACE inhibitor, approved by the FDA in 1981. [2] — Peter Attia "Captopril FDA approved 1981 — first oral ACE inhibitor: Captopril, designed using a venom peptide from Brazilian pit viper as its structura…" 25:00 From captopril came enalapril, lisinopril, ramipril, and ultimately the angiotensin receptor blockers. The renin-angiotensin-aldosterone system is now one of the most drugged pathways in medicine. The causal chain from a Brazilian snake farm to tens of millions of lives saved spans 70 years and five countries — and nobody in it set out to treat hypertension.
Maurício Rocha e Silva wasn't looking for bradykinin — he was testing a wrong hypothesis about histamine and circulatory shock. The accidental discovery of bradykinin, then of BPF, then of ACE's dual role in blood pressure, handed medicinal chemists a structural lead for captopril that no one had designed from first principles.
Captopril, designed using a venom peptide from Brazilian pit viper as its structural lead, was approved by the FDA in 1981 as the first oral ACE inhibitor in clinical use.
The entire ACE inhibitor drug class, from bradykinin's discovery in the 1940s to captopril's FDA approval in 1981, emerged from roughly 70 years of sequential curiosity-driven research without anyone initially intending to treat hypertension.
In Dan Ariely's door experiment, participants sacrificed the highest-reward door — repeatedly — just to avoid seeing other doors disappear. Even when researchers trained them to use the best door, they kept wasting clicks to maintain options. This is the bias that runs our lives: we'll take a worse outcome to preserve the feeling of optionality.
Dan Gilbert discovered that the brain has a 'psychological immune system' — it misremembers, reframes, and rationalizes to keep you satisfied with whatever you chose. The fear before commitment is all about potential regret. But after committing, your brain quietly starts justifying the choice — and the more irreversible the decision, the stronger the effect.
The psychological immune system can get you through the first few months of any commitment. But durable, long-term well-being requires self-concordance — choosing commitments that are genuinely aligned with your values and what you actually want. Without that alignment, the satisfaction fades fast.
Vision didn't just help animals find food — it ignited the Cambrian explosion of speciation. Half of the human cortex is devoted to visual processing, and that same visual hierarchy directly inspired the neural network architectures powering today's AI.
Peptides come loaded with a powerful narrative: regenerative, subcutaneous, targeted, cutting-edge. That narrative can genuinely move outcomes, especially for pain, energy, and recovery. The RCT's job is to quantify how much additional benefit comes from the molecule itself — above and beyond the compelling story surrounding it.
A pharmaceutical is not an amino acid sequence — it is the successful solution to manufacturing, purification, formulation, and consistency challenges. When clinical trials prove a drug works, they validate a specific product under specific processes, not every preparation that shares the same sequence.
Ask one question of any peptide advocate: what evidence would prove this claim wrong? If every disappointing result gets attributed to wrong dose, bad supplier, wrong timing, or improper stacking, the hypothesis is not falsifiable — and a non-falsifiable claim is not a scientific claim.
When you vividly imagine something, your visual, auditory, and motor cortices light up almost identically to when it actually happens. This means daily visualization is genuine neural training — not wishful thinking.
Reality has gaps — and you fill them with stories. When you meet someone new and instantly form an impression, that's not perception, it's imagination. Recognizing this is the first step to changing the story.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.